Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026Expert Opinion on PharmacotherapyOpen Access

Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia

View Full Paper
Ask AI
Bookmark
Share

Authors

CECamille V. EdwardsJCJorge J. CastilloTMTarek H. Mouhieddine

Discussion

Loading...

Member takes

Overview

Review outlines therapeutic developments and emerging strategies in Waldenström macroglobulinemia, highlighting the need for biologically informed treatment sequencing.

Key Points

  • Review existing chemoimmunotherapy regimens, targeted therapies, and emerging strategies for Waldenström macroglobulinemia while assessing current clinical challenges in disease management.
  • Narrative synthesis evaluating clinical efficacy, toxicity profiles, and treatment paradigms of chemoimmunotherapy and Bruton tyrosine kinase inhibitors.
  • Assessment of emerging novel therapeutics, combination regimens, and key clinical considerations regarding response depth and long-term outcomes.
  • Targeted agents and modern chemoimmunotherapy yield substantial improvements in disease control and progression-free survival relative to historic regimens.
  • The therapeutic landscape lacks definitive head-to-head comparative data, leaving the optimal sequencing of available agents and mitigation of cumulative toxicities unresolved.

Cite This Study

Edwards et al. (2026) studied this question.

synapsesocial.com/papers/6aabb73d5f706d05830e6325https://doi.org/10.1080/14656566.2026.2734125
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 20252026
  2. 2Current Approaches in the Management of Monoclonal Gammopathies: an approach to Waldenström Macroglobulinemia2024
  3. 3Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.2024 · 11 citations
  4. 4Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience2026
  5. 5Clinical Characteristics and Treatment Outcome of Waldenstrom Macroglobulinemia: Experience from a Tertiary Cancer Centre2024 · 1 citations